Patents Examined by Jeanine Goldberg
  • Probe matrix-based device for identifying microorganisms
    Patent number: 7449328
    Abstract: Device for identifying microbial organisms using a collection of polynucleotide probes, each probe having binding specificity for the ribosomal nucleic acids of at least one microbe. The collection of probes is organized into a series of “addresses” that provide information about the presence or absence of one or more polynucleotide sequences in the biological sample. The system is particularly suited to automated analysis.
    Type: Grant
    Filed: August 30, 2004
    Date of Patent: November 11, 2008
    Assignee: Gen-Probe Incorporated
    Inventor: James J. Hogan
  • Detecting mutations in the feline cardiac myosin binding protein C gene associated with hypertrophic cardiomyopathy in cats
    Patent number: 7442509
    Abstract: The invention pertains to methods for detecting the presence or absence of a mutation associated with hypertrophic cardiomyopathy in cats, particularly domesticated cats, and more particularly Maine Coon cats. The methods include detecting the presence or absence of a mutation in the feline MYBPC gene, and identifying feline subjects that have or are at risk of developing hypertrophic cardiomyopathy.
    Type: Grant
    Filed: June 1, 2006
    Date of Patent: October 28, 2008
    Assignees: The Ohio State University Research Foundation, University of California, Davis
    Inventors: Kathryn Meurs, Mark Kittleson
  • Genetic test for PSE-susceptible turkeys
    Patent number: 7432057
    Abstract: This invention relates to methods and compounds for the improvement of turkey meat and turkey populations, but not limited to, a genetic screen to select for turkeys that produce a better quality of meat characterized by a higher postmortem pH and better water holding capacity.
    Type: Grant
    Filed: January 27, 2005
    Date of Patent: October 7, 2008
    Assignee: Michigan State University
    Inventors: Wen Chiang, Gale Strasburg, John Linz
  • PITX2 polynucleotide, polypeptide and methods of use therefor
    Patent number: 7427476
    Abstract: A novel T-type calcium channel (CACNA1G) is provided, as are polynucleotides encoding the same. CACNA1G has been implicated in cellular proliferative disorders. More specifically, it has been observed that the methylation state of specific regions within CpG islands associated with the CACNA1G gene correlates with a number of cancerous phenotypes involving a variety of tissue and cell types. Also provided are methods for detecting cellular proliferative disorders by determining the methylation state of genes or regulatory regions associated therewith, including CACNA1G, as well as kits containing reagents for performing invention methods.
    Type: Grant
    Filed: August 30, 2004
    Date of Patent: September 23, 2008
    Assignee: The Johns Hopkins University School of Medicine
    Inventor: Jean-Pierre Issa
  • Methods of assessing the risk for the development of sporadic prostate cancer
    Patent number: 7427482
    Abstract: The invention concerns the genomic sequence of the purH gene. The invention also concerns biallelic markers of a purH gene and the association established between these markers and cancer, particularly prostate cancer. The invention provides means to determine the predisposition of individuals to cancer as well as means for the diagnosis of cancer and for the prognosis/detection of an eventual treatment response to agents acting on cancer.
    Type: Grant
    Filed: November 22, 2005
    Date of Patent: September 23, 2008
    Assignee: Serono Genetics Institute S.A.
    Inventors: Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret, Annick Cohen-Akenine
  • Canine CYP1A2 genetic polymorphism
    Patent number: 7399587
    Abstract: Disclosed is a method for determining whether a dog is an extensive metabolizer or a poor metabolizer in the rate of drug metabolism, by preparing a DNA sample from a dog, and determining a base corresponding to a base at position 1117 of a canine CYP1A2 gene (i.e., at position 87 of exon 4). According to the method, a CYP1A2 gene diagnosis of dogs (particularly beagles) used in a pharmacological effect test or a toxicity test can be rapidly carried out prior to the test, and thus the dogs can be easily divided into a group having a normal metabolic ability (an extensive metabolizer group) and a group having a low metabolic ability (a poor metabolizer group).
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: July 15, 2008
    Assignee: Astellas Pharma Inc.
    Inventors: Daisuke Tenmizu, Yasuhisa Fukunaga, Kiyoshi Noguchi
  • Alien sequences
    Patent number: 7396646
    Abstract: The present invention provides sequences and reagents for preparing microarrays with internal controls. Specifically, the present invention defines and provides sequences that are not present in the hybridizing mRNA or cDNA, and therefore can be used both as hybridization controls and for inter-spot normalization.
    Type: Grant
    Filed: September 12, 2005
    Date of Patent: July 8, 2008
    Assignees: Modular Genetics, Inc., Trustees of Boston University
    Inventors: Sean Quinlan, Temple Smith, Prashanth Vishwanath
  • Compositions and kits for detecting a sequence mutation in cinnamyl alcohol dehydrogenase gene associated with altered lignification in loblolly pine
    Patent number: 7396921
    Abstract: Loblolly pine (Pinus taeda L.) is the most important commercial tree species in the USA harvested for pulp and solid wood products. Increasing the efficiency of chemical pulping may be achieved through the manipulation of genes involved in the lignin biosynthetic pathway. A null allele of cinnamyl alcohol dehydrogenase (CAD) has been discovered in the loblolly pine clone 7-56 which displays altered lignin composition. During identification of single nucleotide polymorphisms (SNPs) in the cad gene, a two-base pair adenosine insertion located in exon five and unique to clone 7-56 was discovered. The sequence mutation causes a frame-shift predicted to result in premature termination of the protein. For routine detection of the mutation, a diagnostic assay was developed utilising Template-directed Dye-terminator Incorporation and Fluorescence Polarization detection (FP-TDI).
    Type: Grant
    Filed: June 16, 2005
    Date of Patent: July 8, 2008
    Assignees: The Regents of the University of California, The United States of America as represented by the Secretary of Agriculture
    Inventors: Geoffrey P. Gill, Garth R. Brown, David B. Neale
  • Methods and primers for diagnosing idiopathic congenital central hypoventilation syndrome
    Patent number: 7393642
    Abstract: The present invention provides assays and kits for diagnosing idiopathic congenital central hypoventilation syndrome. The present assays and kits focus on the second polyalanine repeat of the PHOX2b gene or gene product, which is normally 20 residues in length. A polyalanine repeat 25 to 33 residues in length is strongly correlated with idiopathic congenital central hypoventilation syndrome.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: July 1, 2008
    Assignee: Chicago Community Foundation
    Inventors: Debra E. Weese-Mayer, Elizabeth M. Berry-Kravis, Lili Zhou
  • Method of detecting ivermectin sensitivity in a canine subject by identifying a mutation in a MDR1-encoding sequence
    Patent number: 7393643
    Abstract: This invention provides the identification of a truncation polymorphism of the mdr1 gene that is linked to ivermectin sensitivity in subjects, such as collies. Also provided are methods for detecting drug transport sensitivity in a subject, and animal models and in vitro cell systems using cells from animals having an mdr1 truncation.
    Type: Grant
    Filed: July 21, 2004
    Date of Patent: July 1, 2008
    Assignee: Washington State University Research Foundation
    Inventor: Katrina L. Mealey
  • Method and nucleic acids for the differentiation of prostate tumors
    Patent number: 7381808
    Abstract: The present invention relates to chemically modified genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for ascertaining genetic and/or epigenetic parameters of genes for use in characterisation, classification, differentiation, diagnosis and therapy of prostate lesions.
    Type: Grant
    Filed: June 13, 2002
    Date of Patent: June 3, 2008
    Assignee: Epigenomics AG
    Inventors: Juergen Distler, Fabian Model, Peter Adorjan
  • Gene functionally related to dyslexia
    Patent number: 7355022
    Abstract: The present invention describes a novel human gene, DYXC1, which is functionally related to dyslexia. DYXC1 gene encodes a 420-amino acid residue protein. DYXC1 is expressed in several tissues, including the brain, and is localized in the nucleus. In addition, four single nucleotide polymorphisms (SNPs) in DYXC1 mRNA have been characterized in this invention. The invention provides diagnostic methods and materials for analysing allelic variation in DYXC1 gene. This invention also provides polypeptides encoded by DYXC1 gene and antibodies binding to said polypeptides.
    Type: Grant
    Filed: October 9, 2003
    Date of Patent: April 8, 2008
    Assignee: Licentia Ltd.
    Inventors: Juha Kere, Mikko Taipale, Jaana Nopola-Hemmi, Nina Kaminen
  • Probes, compositions and kits for determining the presence of in a test sample
    Patent number: 7345155
    Abstract: The present invention relates to oligonucleotides useful for determining the presence of Mycoplasma pneumoniae and/or Mycoplasma genitalium in a test sample. The oligonucleotides of the present invention may be incorporated into hybridization assay probes, capture probes and amplification primers, and used in various combinations thereof.
    Type: Grant
    Filed: October 31, 2002
    Date of Patent: March 18, 2008
    Assignee: Gen-Probe Incorporated
    Inventors: Melissa M. Cunningham, James P. Light, II
  • Detection and quantification of human herpes viruses
    Patent number: 7338761
    Abstract: In clinical settings as well as in a drug development context, human herpes viruses can be detected, and even quantified, by the use of a real time PCR-based assay. An informatics analysis of existing gene sequences from different HHV types or strains is used to identify a target segment within a gene. A probe oligonucleotide and at least two primer oligonucleotides are then designed for selectively directing the amplification, in the course of a single amplification reaction, of the target segment of a particular HHV type or strain. This method is capable of an unprecedented level of discrimination among the following HHV types and strains: HHV1, drug resistant HHV1, HHV2, drug resistant HHV2, HHV3, HHV4a, HHV4b, HHV5, HHV6a, HHV6b, HHV7, and HHV8.
    Type: Grant
    Filed: October 12, 2001
    Date of Patent: March 4, 2008
    Assignee: Vigen Laboratories Inc.
    Inventors: Thomas R. Reynolds, Robert B. Harris
  • Compositions and methods for detecting and treating neurological conditions
    Patent number: 7332282
    Abstract: The present invention relates to the NIPA-1 proteins and nucleic acids encoding the NIPA-1 proteins. The present invention further provides assays for the detection of NIPA-1 polymorphisms and mutations associated with disease states, as well as methods of screening for ligands and modulators of NIPA-1 proteins.
    Type: Grant
    Filed: August 19, 2004
    Date of Patent: February 19, 2008
    Assignee: The Regents of the University of Michigan
    Inventors: John K. Fink, Shirley Rainier, Robert D. Nicholls, Jinghua Chai
  • Large scale genotyping of diseases and a diagnostic test for spinocerebellar ataxia type 6
    Patent number: 7329487
    Abstract: The present invention provides a method of screening individuals at risk for developing diseases caused by trinucleotide repeat sequence instability. Specifically, the present invention is drawn to screening individuals at risk for developing autosomal dominant spinocerebellar ataxia type 6 by determining the length of a CAG trinucleotide repeat in the ?1A calcium channel gene of the individual. In addition, there is provided a method of identifying genes which are disease-causing due to trinucleotide repeat sequence instability by large scale genotyping.
    Type: Grant
    Filed: May 12, 2003
    Date of Patent: February 12, 2008
    Assignee: Research Development Foundation
    Inventor: Cheng-Chi Lee
  • Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis
    Patent number: 7317097
    Abstract: The present invention relates to mutations in the gene coding for ferroportin 1 associated with hereditary haemochromatosis and methods for the diagnosis of hereditary haemochromatosis based on the identification of such mutations.
    Type: Grant
    Filed: October 17, 2001
    Date of Patent: January 8, 2008
    Inventor: Antonello Pietrangelo
  • ?-catenin oligonucleotide microchip and method for detecting ?-catenin mutations employing same
    Patent number: 7312070
    Abstract: The present invention relates to a ?-catenin oligonucleotide microchip for detecting mutation in the mutational hot spot regions of ?-catenin gene, a manufacturing process thereof and a method for detecting the ?-catenin mutation employing same, wherein specific oligonucleotides are selectively designed to detect various missense mutations and in-frame deletion at the mutational hot spots of ?-catenin gene. The ?-catenin oligo chip of the present invention can be used in studies to detect ?-catenin mutations and unravel the signal transduction mechanism and tumorigenesis related to ?-catenin gene.
    Type: Grant
    Filed: September 9, 2003
    Date of Patent: December 25, 2007
    Assignee: National Cancer Center
    Inventors: Jae-Gahb Park, Il-Jin Kim, Hio-Chung Kang, Jae-Hyun Park
  • CFTR allele detection assays
    Patent number: 7312033
    Abstract: The present invention provides compositions and methods for the detection and characterization of mutations associated with cystic fibrosis. More particularly, the present invention provides compositions, methods and kits for using invasive cleavage structure assays (e.g. the INVADER assay) to screen nucleic acid samples, e.g., from patients, for the presence of any one of a collection of mutations in the CFTR gene associated with cystic fibrosis. The present invention also provides compositions, methods and kits for screening sets of CFTR alleles in a single reaction container.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: December 25, 2007
    Assignee: Third Wave Technologies, Inc.
    Inventors: Molly Accola, Susan S. Wigdal, Andrea L. Mast, Christian T. Bartholomay, Robert W. Kwiatkowski, Jr., Vincent Tevere, Hon S. Ip
  • Identification of the gene and mutation responsible for progressive rod-cone degeneration in dog and a method for testing same
    Patent number: 7312037
    Abstract: Tools and methods are provided for determining whether or not a dog is genetically normal, is a carrier of, or is affected with or predisposed to progressive rod-cone degeneration. The method is based on the detection of a transversion from G to A at position corresponding to nucleotide position 1298 of SEQ ID NO: 1.
    Type: Grant
    Filed: June 21, 2005
    Date of Patent: December 25, 2007
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Gustavo Aguirre, Gregory M. Acland, Barbara Zangerl, Orly Goldstein, Susan Pearce-Kelling, Jeanette S. Felix, Duska J. Sidjanin